In one line
Lichen sclerosus is a chronic, autoimmune, scarring inflammatory dermatosis of the anogenital skin whose two consequences — progressive architectural destruction and a lifetime vulvar squamous-cell-carcinoma risk of around 3.5–5% — are both substantially preventable by lifelong, individualised ultrapotent topical corticosteroid titrated to normal-looking skin, which makes long-term suppression and malignancy surveillance, not the initial diagnosis, the consultant task.
Mechanism & pathophysiology
The basic histology and clinical recognition of lichen sclerosus are assumed here; the groundwork sits in the Intermediate chapter on lichen sclerosus, and the premalignant vulvar epithelial changes in vulvar epithelial hyperplasia and vulval carcinoma. What a consultant must hold is the immunology that explains both the scarring and the cancer.
Lichen sclerosus (LS) is a T-cell-driven, predominantly T-helper-1, miR-155-dependent inflammatory disease of genital skin and mucosa. The inflammatory infiltrate sits at the dermo-epidermal junction, and the characteristic upper-dermal change is homogenised, hyalinised collagen overlying a band of lymphocytes — sclerosis that is the structural correlate of the clinical scarring. The basement-membrane zone is disrupted, with altered collagen IV and VII; against that disrupted zone, circulating IgG autoantibodies to extracellular matrix protein 1 (ECM1) are found in roughly three-quarters of patients (74% in the original series versus 7% of controls), the strongest single piece of evidence that LS is an acquired autoimmune disorder rather than a purely degenerative one. ECM1 normally regulates basement-membrane and dermal architecture; loss of its function (genetically in lipoid proteinosis, autoimmune in LS) produces the hyaline dermal change.
The disease keeps autoimmune company. Thyroid autoimmunity — Hashimoto thyroiditis and Graves disease — is markedly over-represented, found in about 18.9% of women with LS against 5.1% of male patients, an odds ratio near 2.88. Vitiligo, alopecia areata, pernicious anaemia and type 1 diabetes cluster similarly. The practical inference is to screen symptomatically for thyroid disease and treat LS as a marker of an autoimmune diathesis, not an isolated skin complaint.
The cancer pathway is the part that reorders management. Vulvar squamous cell carcinoma (SCC) arises by two biologically distinct routes. The HPV-associated route runs through high-risk HPV infection, usual-type VIN (now vulvar HSIL) to basaloid or warty SCC in younger women — the same E6/E7-driven inactivation of p53 and Rb that drives cervical disease, and the reason the HPV vaccine is relevant to vulvar as well as cervical cancer. The HPV-independent route runs through lichen sclerosus: chronic inflammation drives clonal expansion of keratinocytes that acquire TP53 mutations, producing differentiated VIN (dVIN) — p16-negative, with aberrant (mutant-pattern) p53 on immunohistochemistry and frequently CK17-positive — which progresses to keratinising SCC in older, post-menopausal women. This is the more dangerous lineage: dVIN is subtle, often unifocal and arising in a field of existing dermatosis rather than as an obvious warty plaque, it progresses to invasion faster than HPV-associated HSIL, and the SCC it produces recurs more often. Up to about 65% of vulvar carcinomas arise on a background of vulvar LS, and SCC is observed in roughly 3.5–7% of women with LS over time — so LS is not a benign itch but a premalignant condition whose malignant potential runs by the HPV-independent route and is therefore not prevented by HPV vaccination (which protects only against the separate HPV-associated vulvar disease), making surveillance essential.
Lichen planus (LP) is an overlapping but separate entity, also a T-cell-mediated interface dermatosis but classically with a lichenoid band of lymphocytes hugging the epidermis, Civatte (apoptotic keratinocyte) bodies, and saw-tooth rete ridges. Its dangerous vulvar form is erosive lichen planus, which destroys the vestibule and vagina (LS spares the vagina), can fuse the introitus and obliterate the vaginal canal, and — as part of the vulvovaginal-gingival syndrome — affects the mouth and gingivae simultaneously. Erosive vulvar LP also carries a malignant-transformation risk, lower than but analogous to LS.
Differentiated VIN — the molecular detail that drives surveillance
dVIN is worth understanding at the level of the cell, because its biology explains why it is both dangerous and easy to miss. Unlike HPV-associated HSIL, where viral E6/E7 oncoproteins functionally inactivate wild-type p53 (so the tumour cells express normal-length p53 abnormally, and p16 is driven block-positive as a surrogate of HPV transcription), dVIN arises from somatic TP53 mutation in keratinocytes chronically inflamed by LS. The mutant p53 may be over-expressed (a strong, continuous "mutant pattern" on immunohistochemistry) or completely absent ("null pattern") — either deviation from the patchy "wild-type" staining of normal epithelium signals dysfunction. Under the 2026 ISSVD terminology, HPV-independent VIN is itself subcategorised into p53-mutant and p53-wild-type forms, so not every HPV-independent precursor carries a TP53 mutation, though the LS-associated dVIN seen here is the p53-mutant type. Crucially p16 is negative because there is no HPV. The architectural and cytological atypia of dVIN is confined to the basal and parabasal layers with paradoxical surface maturation, so on a casual section it can read as benign reactive or hyperplastic epithelium — which is exactly why a pathologist must be told to look for it, and why p53 and p16 immunohistochemistry are requested explicitly rather than left to routine reporting. CK17 positivity adds support. The consequence for the clinic is that dVIN has a short latency and high rate of progression to invasive keratinising SCC — far higher than HPV-associated HSIL — so its detection is the entire justification for lifelong surveillance of LS.
Assessment
The history is of chronic vulvar itch (LS, often nocturnal and intractable) or soreness and dyspareunia (erosive LP), frequently mislabelled and self-treated as recurrent thrush for years. Ask directly about loss of architecture the woman may have noticed (a "shrinking" or "sealing" introitus, splitting with intercourse or defecation), urinary spraying or deflection (clitoral hood fusion, introital narrowing), and any persistent localised lump, ulcer, raw area or new bleeding — the symptoms that signal malignant change. Screen for personal and family autoimmune disease and for oral or other mucosal symptoms.
Examination is the diagnosis. The hallmarks to document, because they are what change management:
- Lichen sclerosus — porcelain-white, atrophic, "cigarette-paper" crinkled skin in a figure-of-eight around the vulva and perianus (sparing the vagina), with ecchymoses/purpura from fragile dermis, fissuring, and hyperkeratosis. The architectural endpoints are loss of the labia minora (resorption/fusion to the labia majora), fusion of the clitoral hood with clitoral burying (phimosis), midline fusion, and introital stenosis — these are scarring, not active inflammation, and once established they do not reverse with steroid.
- Lichen planus — in the erosive form, glazed bright-red erosions of the vestibule and inner labia, often with a hyperkeratotic Wickham-striae-like white reticulate border, vaginal involvement with synechiae and a serosanguinous discharge, and frequent concurrent oral disease. Architectural destruction (introital and vaginal stenosis) follows.
- Differentiating mimics — vitiligo is depigmentation without textural change, atrophy, scarring or symptoms; chronic dermatitis/lichen simplex is lichenified, leathery, intensely itchy skin from the itch-scratch cycle without the white sclerosis or architectural loss; psoriasis, candidiasis and extramammary Paget disease enter the differential of a red or itchy vulva. The discriminator is the combination of colour change, texture (atrophy/sclerosis) and architectural loss, none of which a simple dermatitis produces.
When to biopsy is the consultant judgement, because LS and LP are usually clinical diagnoses but biopsy is mandatory when malignancy is in play:
- Any focal abnormality within the dermatosis — a non-healing erosion or ulcer, a persistent lump, nodule, warty or hyperkeratotic plaque, fixed erythema, or new bleeding.
- Failure of an adequate, adherent course of ultrapotent topical corticosteroid, once adherence, application technique and superinfection have been checked — this can flag underlying dVIN or invasion that the steroid will never clear. Relapse after stopping is the expected natural history of a chronic disease and calls for re-induction and maintenance, not automatic biopsy.
- Diagnostic uncertainty, atypical features, or before starting long-term immunosuppression where the diagnosis is not secure.
- Suspected dVIN or SCC — biopsy generously and from the most abnormal point, because dVIN is histologically subtle and easily under-read; ask the pathologist specifically for p53 and p16 (mutant-pattern p53 with negative p16 supports dVIN; block-positive p16 points to HPV-associated HSIL instead) and CK17 where available.